Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
Sign Up to like & getrecommendations! Published in 2018 at "Revista espanola de cardiologia"
DOI: 10.1016/j.rec.2017.10.009
Abstract: INTRODUCTION AND OBJECTIVES Acute coronary syndrome (ACS) guidelines recommend the use of newer P2Y12 inhibitors (prasugrel and ticagrelor) over clopidogrel in patients with moderate-to-high ischemic risk, unless they have an increased bleeding risk. The aim… read more here.
Keywords: risk; bleeding risk; risk scores; newer p2y12 ... See more keywords
Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-73871-x
Abstract: Whether newer P2Y12 inhibitors are more efficacious and safer than clopidogrel and whether there is a superior one remain uncertain. We compared the effect of P2Y12 inhibitors on clinical outcomes in patients with acute coronary… read more here.
Keywords: prasugrel; clopidogrel; ticagrelor; acute coronary ... See more keywords